Camber Capital Management’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Camber Capital Management’s Portfolio ARIA Stock Details ARIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-4,000,000	Closed	-$29.6M	–	47
2016 Q2	$29.6M	Sell	4,000,000 -1,405,235	-26%	-$10.5M	1.43%	29
2016 Q1	$34.5M	Hold	5,405,235	–	–	2.02%	25
2015 Q4	$33.8M	Sell	5,405,235 -127,883	-2%	-$839K	2.18%	23
2015 Q3	$32.3M	Sell	5,533,118 -216,882	-4%	-$1.67M	2.77%	15
2015 Q2	$47.6M	Sell	5,750,000 -1,250,000	-18%	-$11.1M	3.24%	17
2015 Q1	$57.7M	Sell	7,000,000 -500,000	-7%	-$3.7M	4.12%	7
2014 Q4	$51.5M	Buy	7,500,000 +1,500,000	+25%	+$9.38M	3.43%	9
2014 Q3	$32.4M	Buy	6,000,000 +1,000,000	+20%	+$5.84M	3.04%	15
2014 Q2	$31.9M	Buy	5,000,000 +2,000,000	+67%	+$13.8M	2.09%	19
2014 Q1	$24.2M	Sell	3,000,000 -2,250,000	-43%	-$17.5M	1.89%	17
2013 Q4	$35.8M	Buy	+5,250,000	New	+$28.3M	3.16%	15

Other funds holding ARIA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Camber Capital Management's ARIA Position: Q3 2016 in Review

Camber Capital Management sold out of Ariad Pharmaceuticals Inc (ARIA) in Q3 2016, closing a stake of 4,000,000 shares — an estimated $29.6M sold.

Camber Capital Management first reported a position in ARIA in Q4 2013 and held it in 11 quarters. The position peaked at $57.7M in Q1 2015. 202 funds tracked by Wall St. Rank hold ARIA as of Q3 2016.

Camber Capital Management reported no remaining Ariad Pharmaceuticals Inc position as of Q3 2016 after selling out during the quarter.
Camber Capital Management sold 4,000,000 Ariad Pharmaceuticals Inc shares in Q3 2016, an estimated $29.6M.
Camber Capital Management first reported a position in Ariad Pharmaceuticals Inc in Q4 2013 and held it in 11 quarters.
Camber Capital Management's Ariad Pharmaceuticals Inc position peaked at $57.7M in Q1 2015.
202 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q3 2016.

Based on Camber Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.